Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo

Inclusion Criteria: * The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol. * The subject is between 18 and 70 years of age (including borderline values) , regardless of gender. Exclusion Criteria: * Pregnant or lactating women, or subjects with pregnancy or lactation plans during the study period. * All hair in the vitiligo area on the face is white. * Those who are known or suspected to be allergic to the main ingredients and excipients of VC005 or similar drugs. * Subjects who have previously received depigmentation treatment. * Subjects who have received experimental drug administration or participated in device clinical trials within the first month or 5 half lives (whichever is longer) prior to randomization.